Related Experiment Video
Updated: Mar 23, 2026

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
Published on: August 20, 2019
The impact of early human data on clinical development: there is time to win
Piet Swart1, Frederic Lozac'h1, Marjorie Simon1
1Drug Metabolism and Pharmacokinetics, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Fabrikstrasse 14, CH4001 Basel, Switzerland.
Abstract:
Modern accelerator mass spectrometry (AMS) methods enable the routine application of this technology in drug development. By the administration of a (14)C-labelled microdose or microtrace, pharmacokinetic (PK) data, such as mass balance, metabolite profiling, and absolute bioavailability (AB) data, can be generated easier, faster, and at lower costs. Here, we emphasize the advances and impact of this technology for pharmaceutical companies. The availability of accurate intravenous (iv) PK and human absorption, distribution, metabolism, and excretion (ADME) information, even before or during Phase I trials, can improve the clinical development plan. Moreover, applying the microtrace approach during early clinical development might impact the number of clinical pharmacology and preclinical safety pharmacology studies required, and shorten the overall drug discovery program.
Related Concept Videos
Preclinical Development: Overview
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Drug Discovery: Overview
Bioavailability Study Design: Healthy Subjects Versus Patients
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

